A photodynamic immunostimulant called BVC, which reprograms tumor metabolism through inhibition of glutamine transport and GSH synthesis, leads to an increased immune response and blockade of the PD-1/PD-L1 immune checkpoint, which in turn leads to effective treatment of metastatic tumors. The gene discussed is CD274; the disease is neoplasm.